axi-celAxicabtagene Ciloleucelrelapse/refractory LBCLCAR T-cell therapy
…n expanded multi-trial meta-cohort of 586 patients treated with axi-cel. Product characterization was performed with scRNAseq and scATA…
7articles mentioning drugs
42drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Axi-cel ×
Axi-cel
This drug is selected. Its supporting articles are shown below.
Articles mentioning Axi-cel
7 articles · page 1 of 1tisagenlecleuceltisa-celaxi-celaxicabtagene ciloleucel
…eater real-world efficacy and cytokine-associated toxicity than tisagenlecleucel (tisa-cel; CD19/4-1BB), for reasons that are poorly understood.…
axi-celAxicabtagene ciloleucelsiltuximabdexamethasonemethylprednisoloneanakinratocilizumabDiffuse large B-cell lymphoma (DLBCL)DLBCLnon-Hodgkin lymphomas
…mplications.Conclusion and Relevance In this real-world cohort, axi-cel showed predictable but significant toxicity, including universa…
Axi-celaxicabtagene ciloleucelDiffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphomasDLBCL
…, 1 (64.9%; 24p). Seven had prior transplants: five autologous. Axi-cel was: 78.4% third-line; 18.9% fourth-line, 2.7% sixth-line. Medi…
brexucabtagene autoleucelbrexi-celtisagenlecleucelaxicabtagene ciloleuceltisa-celaxi-celmyelomatertiary oncology centrechemo refractory aggressive B-cell lymphomas
…l (axi-cel), 31 (42%) tisagenlecleucel (tisa-cel), and 11 (16%) brexucabtagene autoleucel (brexi-cel). Mean V2Vt was 48±19 days (median 42) for axi-cel, …
axicabtagene ciloleucelaxi-cel
…ior outcome for patients receiving anti-CD19 CAR-T cell therapy axicabtagene ciloleucel (axi-cel) versus historical standard of care. However, about 60…
polatuzumabrituximabAxi-celdarunaviraxicabtagene ciloleucelemtricitabinefludarabinetenofovirnon-Hodgkin lymphomaonco-hematological malignancies+1 more
…y with axicabtagene ciloleucel (axi-cel). Bridging therapy with polatuzumab plus rituximab, followed by Axi-cel infusion after a standard l…